The company’s lead candidate, GLSI-100, relies on this specific batch of GP2 to prevent breast cancer from returning. While the stock currently trades at $19.66, it remains down 3.2% for the year. This European authorization allows clinical sites to align their protocols with the U.S. supply chain, which has utilized the same lot since early 2026.

Operations are scaling rapidly, with the total number of participating clinical sites across both regions now reaching between 170 and 180. Shipments of the ingredient are currently moving toward European pharmacies. Simultaneously, Greenwich LifeSciences is navigating independent regulatory pathways in the United Kingdom and Canada to secure further approval for the same manufacturing lot.